Related Experiment Video
Updated: May 9, 2026

Developing a Rat Model for Bipolar Disorder
Published on: May 2, 2025
Current and emerging therapies for the management of bipolar disorders
Rif S El-Mallakh1, Ahmed Z Elmaadawi, Yonglin Gao
1Mood Disorders Research Program, Department of Psychiatry and Behavioral Sciences, University of Louisville School of Medicine, Louisville, Kentucky, USA.
Abstract:
Bipolar disorder is a complex condition to treat because agents that may be effective for a specific phase may not be effective for other phases, or may even worsen the overall course of the illness. Over the last decade there has been an increase in research activity in the treatment of bipolar illness. There are now several agents that are well established for the treatment of acute mania (lithium, divalproex, carbamazepine, nearly all antipsychotics), acute bipolar depression (lamotrigine, quetiapine, olanzapine/fluoxetine combination), and relapse prevention (lithium, lamotrigine, divalproex, most second generation antipsychotics). There are also novel treatments that are being studied for all three phases. These include eslicarbazepine, cariprazine, MEM-1003, memantine, tamoxifen and pentazocine for acute mania; pramipexole, modafinil, armodafinil, divalproex, lurasidone, agomelatine, cariprazine, lisedexamfetamine, riluzole, RG-2417, bifeprunox, ropinirole, GSK1014802, and magnetic stimulation for bipolar depression; and asenapine, lurasidone, and cariprazine for relapse prevention. Additionally, there are accumulating data that antidepressants, particularly serotoninergic ones, are not particularly effective in acute bipolar depression and may worsen the course of the illness.
Related Concept Videos
Mania and Antimanic Drugs: Overview
Drug Therapy
Antianxiety Medications
Bipolar Disorder
Electroconvulsive Therapy
Psychosis: Goals of Pharmacotherapy
Antidepressant Drugs: MAOIs and Other Agents